NCT04990323View on ClinicalTrials.gov

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
High Risk Myeloid MalignanciesCord Blood Transplant
Interventions
BIOLOGICAL

ECT-001-CB (UM171-Expanded Cord Blood Transplant)

Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Lead Sponsor

ExCellThera inc.
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

ExCellThera inc.

INDUSTRY

NCT04990323 - US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies | Biotech Hunter | Biotech Hunter